• Occurrence of severe RV GE caused by the wild RV strains [ Time Frame: During the period starting from 2 weeks after Dose 2 until two years of age ]
  
• Occurrence of definite Intussusception (IS) cases [ Time Frame: Within 31 days after each vaccination ]
  

• Occurrence of severe RV GE caused by the wild RV strain of serotype G1 [ Time Frame: During the period starting from 2 weeks after Dose 2 until two years of age ]
  
• Occurrence of severe RV GE due to non-G1 serotypes [ Time Frame: During the period starting from 2 weeks after Dose 2 until two years of age ]
  
• Occurrence of severe RV GE due to each non-G1 serotype [ Time Frame: During the period starting from 2 weeks after Dose 2 until two years of age. ]
  
• Occurrence of severe RV GE caused by the circulating wild-type RV strains, of severe RV GE caused by the wild RV strain of serotype G1, of severe RV GE due to non-G1 serotypes and of severe RV GE due to each non-G1 serotype [ Time Frame: From Dose 1 ]
  
• Occurrence of RV GE caused by the circulating wild-type RV strains and requiring hospitalization and/or re-hydration in a medical facility [ Time Frame: During the period starting from 2 weeks after Dose 2 until two years of age. ]
  
• Occurrence of severe RV GE caused by the circulating wild-type RV strains [ Time Frame: From one year of age up to two years of age ]
  
• Occurrence of severe RV GE caused by the circulating wild-type RV strains [ Time Frame: During the period starting from 2 weeks after Dose 2 until one year of age ]
  
• Occurrence of severe GE [ Time Frame: After Dose 2 until two years of age ]
  
• Occurrence of severe RV GE caused by the wild RV strains [ Time Frame: During the period starting from 2 weeks after Dose 2 until three years of age ]
  
• Occurrence of severe RV GE caused by the wild RV strain of serotype G1. [ Time Frame: During the period starting from 2 weeks after Dose 2 until three years of age ]
  
• Occurrence of severe RV GE due to non-G1 serotypes [ Time Frame: During the period starting from 2 weeks after Dose 2 until three years of age ]
  
• Occurrence of severe RV GE due to each non-G1 serotype [ Time Frame: During the period starting from 2 weeks after Dose 2 until three years of age. ]
  
• Occurrence of RV GE caused by the circulating wild-type RV strains and requiring hospitalization and/or re-hydration therapy in a medical facility [ Time Frame: During the period starting from 2 weeks after Dose 2 until three years of age ]
  
• Occurrence of severe RV GE caused by the circulating wild-type RV strains [ Time Frame: From two years of age up to three years of age ]
  
• Occurrence of severe GE [ Time Frame: During the period starting from two weeks after Dose 2 until three years of age ]
  
• For all subjects, occurrence of serious adverse events (SAEs) [ Time Frame: From Dose 1 until Visit 5 ]
  
• For all subjects, occurrence of definite IS . [ Time Frame: During the period starting from Dose 1 until two years of age ]
  
• For all subjects, occurrence of mortality [ Time Frame: Up to the age of 2 years ]
  
• Serum rotavirus IgA antibody titres in all subjects in a subset of 100 subjects per country [ Time Frame: At visits 1 and 3 ]
  

Note that no new subjects will be recruited in this extension phase studies.

The expected total enrolment for the primary studies was as follows:

rota-028: 5700 rota-029: 3018 rota-030: 1102

Inclusion Criteria:

• Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
• A male or female between, and including, 6 and 12 weeks of age in Hong Kong and Taiwan or 11 to 17 weeks of age in Singapore at the time of the first vaccination according to the country recommendations for the routine vaccination schedules.
• Written informed consent obtained from the parent or guardian of the subject, prior any study procedure.
• Free of obvious health problems as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine or placebo, or planned use during the study period.
• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
• Child is unlikely to remain in the study area for the duration of the study
• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
• History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.
• Administration of immunoglobulins and/or blood products since birth or planned administration during the study period. Oral intake of immunoglobulins is allowed.
• Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition as determined by the investigator.
• First or second degree of consanguinity of parents